Ratings Avantium N.V.

Equities

AVTX

NL0012047823

Market Closed - Euronext Amsterdam Other stock markets 09:05:21 26/04/2024 pm IST			5-day change	1st Jan Change
2.5 ^EUR	+0.20%		+3.73%	-29.08%

21/03	Transcript : Avantium N.V., 2023 Earnings Call, Mar 21, 2024
20/03	Avantium N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Environmental Services & Equipment

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AVANTIUM N.V.	-29.08%	213M		-
BRAIN BIOTECH AG	-21.31%	67.17M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes